“Initiated coverage on Anthem Biosciences with a 'buy' rating and a price target of ₹1,050 per share, implying a 20% upside from Thursday's closing levels. The brokerage expects Anthem's revenue and PAT to grow at a CAGR of 18% and 20% respectively over FY26-29, driven by existing contract scale-up and a robust late-phase project pipeline.”